Resverlogix Receives the US FDA Breakthrough Therapy Designation for Apabetalone
Shots:
- The US FDA has granted BTD for apabetalone in combination with SOC including high-intensity statins- for the secondary prevention of MACE in patients with T2D Mellitus and recent acute coronary syndrome
- In 2019- Resverlogix reported results of P-III BETonMACE that showed a reduction in hospitalizations due to CHF as well as improving CV outcomes in two pre-specified subpopulations including those with CKD
- Apabetalone is a first-in-class- BET inhibitor selective for the second bromodomain (BD2) within the BET proteins
Ref: GLOBE NEWSWIRE | Image: Resverlogix
Click here to read the full press release
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
